SCHEMBL17821171

SCHEMBL17821171

COC(=O)CCn1cc(-n2nnc3cnc(Nc4ccc(OCCCCNC(=O)OC(C)(C)C)cc4)nc32)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 6/20 0.52
▸ GSK3B P49841 6/20 0.52
▸ AURKA O14965 4/20 0.47
▸ EIF2AK4 Q9P2K8 3/20 0.45
▸ ITK Q08881 3/20 0.41
▸ CDK4 P11802 1/20 0.40
▸ CCND3 P30281 1/20 0.40
▸ MAPK6 Q16659 1/20 0.39
▸ CA12 O43570 3/20 0.38
▸ CA1 P00915 3/20 0.38
▸ CA2 P00918 3/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ EGFR P00533 2/20 0.36
▸ JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245530 0.98 GSK3A (0.53) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL16245568 0.94 GSK3A (0.51) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL16245915 0.92 GSK3A (0.52) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL16264886 0.91 GSK3A (0.48) GSK3AGSK3BAURKAEIF2AK4CDK4
SCHEMBL18869177 0.90 GSK3A (0.47) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL17821182 0.90 GSK3A (0.51) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL16245579 0.90 ITK (0.48) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL16245707 0.89 EIF2AK4 (0.47) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL18869321 0.85 GSK3A (0.54) GSK3AGSK3BAURKAEIF2AK4ITK
SCHEMBL16245626 0.84 GSK3A (0.59) GSK3AGSK3BAURKAEIF2AK4ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS EIF2AK4, CDK2, CDK1 GSK3A 523/4885GSK3B 482/4885AURKA 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback